Skip to main content

Advertisement

Table 2 The extracted antidiabetic medication prescription data obtained in the second repeated cross-sectional study

From: Changes in antidiabetic prescription patterns and indicators of diabetic control among 200,000 patients over 13 years at a single institution in Japan

Year 2001 2005 2010 2013 rs# p value#
n 14,996 13,976 17,561 3118   
Sulfonylureas (%) 5102 (34) 4016 (29) 5142 (29) 896 (29)   <0.01*
Glimepiride (n) 197 2414 4399 783   
Glimepiride (mg) 3 (2, 4) [0.5, 6] 2 (1, 3) [0.5, 6] 1 (0.5, 2) [0.5, 6] 1 (0.5, 1.5) [0.5, 6] −0.38 <0.01
Biguanide (%) 3194 (21) 3633 (26) 5432 (31) 1050 (34)   <0.01*
Metformin (n) 3 164 3 622 5 430 1 050   
Metformin (mg) 750 (750, 750) [250, 1000] 750 (750, 750) [250, 1000] 750 (750, 750) [250, 1500] 750 (750, 1500) [250, 2250] 0.36 <0.01
Thiazolidine (%) 338 (2) 1907 (14) 6983 (40) 758 (24)   <0.01*
Pioglitazone (mg) 30 (30, 30) [15, 60] 15 (15, 30) [7.5, 30] 15 (15, 30) [7.5, 45] 15 (15, 30) [7.5, 45] 0.01 0.01
α-GI (%) 2936 (20) 2696 (19) 3966 (23) 561 (18)   <0.01*
Voglibose (n) 2351 2394 3390 493   
Voglibose (mg) 0.6 (0.6, 0.9) [0.2, 0.9] 0.6 (0.6, 0.9) [0.2, 0.9] 0.9 (0.6, 0.9) [0.2, 0.9] 0.9 (0.6, 0.9) [0.3, 0.9] 0.30 <0.01
Meglitinides (%) 654 (4) 1352 (10) 1418 (8) 155 (5)   0.45*
Nateglinide (n) 654 1275 1170 127   
Nateglinide (mg) 270 (270, 270) [60, 360] 270 (180, 270) [30, 360] 270 (180, 270) [30, 360] 270 (120, 270) [60, 360] −0.04 <0.01
DPP4I (%) 0 (0) 0 (0) 361 (2) 1176 (38)   <0.01*
Sitagliptin (n) 0 0 361 818   
Sitagliptin (mg)    50 (50, 50) [25, 100] 50 (25, 50) [25, 100] 0.10 <0.01
Insulins (%) 3550 (24) 5085 (36) 5660 (32) 990 (32)   <0.01*
  1. Median (interquartile range) [range] or n (%)
  2. α-GI α-glucosidase inhibitors, DPP4I dipeptidyl peptidase-4 inhibitors
  3. # Analysis results over 13 years; Additional file 2 shows this in detail
  4. * According to the Cochran-Armitage trend test